Clinical Trials Search Results
Results 1-10 of 185 for your search
Show Search Criteria
Your Search Criteria
Category |
Your Selection |
|---|---|
| Primary Cancer Type/Condition: | Bladder Cancer |
Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 1174 locations
Age: 18 years and over
Gender: Male or Female
Location: 1174 locations
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 845 locations
Age: 18 years and over
Gender: Male or Female
Location: 845 locations
Pembrolizumab in Treating Patients with Locally Advanced Bladder Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 651 locations
Age: 18 years and over
Gender: Male or Female
Location: 651 locations
Atezolizumab in Treating Patients with Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 257 locations
Age: 18 years and over
Gender: Male or Female
Location: 257 locations
Different Versions of BCG with or without Vaccine Therapy in Treating Patients with High Grade Bladder Cancer That Is Not Muscle Invasive
Status: Active
Age: Not specified
Gender: Male or Female
Location: 111 locations
Age: Not specified
Gender: Male or Female
Location: 111 locations
Cisplatin and Gemcitabine Hydrochloride with or without ATR Kinase Inhibitor M6620 in Treating Patients with Metastatic Urothelial Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 30 locations
Age: 18 years and over
Gender: Male or Female
Location: 30 locations
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 25 locations
Age: 18 years and over
Gender: Male or Female
Location: 25 locations
Neratinib HER Mutation Basket Study (SUMMIT)
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 24 locations
Age: 18 years and over
Gender: Male or Female
Location: 24 locations
Sapanisertib in Treating Patients with Locally Advanced or Metastatic Bladder Cancer with TSC1 and / or TSC2 Mutations
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 21 locations
Age: 18 years and over
Gender: Male or Female
Location: 21 locations
Phase 1 / 1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Status: Active
Age: 18 years and over
Gender: Male or Female
Location: 22 locations
Age: 18 years and over
Gender: Male or Female
Location: 22 locations